Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange 07:00:00 10/05/2024 BST 5-day change 1st Jan Change
4,129 JPY +1.45% Intraday chart for Takeda Pharmaceutical Company Limited +0.10% +1.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024 MT
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup DJ
Sector Update: Health Care Stocks Steady Pre-Bell Thursday MT
Transcript : Takeda Pharmaceutical Company Limited, 2024 Earnings Call, May 09, 2024
Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued MT
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update DJ
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss DJ
Japan's Takeda Pharma says full-year profit slumps 56% RE
Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon CI
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year of 2024 CI
Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 2024, Payable June 27, 2024; Provides Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2025 CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer MT
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs CI
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment MT
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease CI
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease DJ
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds MT
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited. CI
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,129 JPY
Average target price
4,768 JPY
Spread / Average Target
+15.48%
Consensus
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Pharmaceutical's Q3 Core Earnings Decline, Revenue Increases